All In Biotech

Drug Trial Radar · NCT03101488

Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors

A Phase I, Single Arm, Multiple Dose, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KN035 Administered in Subcutaneous Injection as a Single Agent to Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

287

Actual

Start

Mar 21, 2017

Primary completion

Sep 2, 2019

Study completion Aug 25, 2020

Sponsor

Sponsor type
Industry
First posted
Apr 5, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This dose escalation and dose expansion study is to evaluate and characterize the tolerability and safety profile of single agent KN035 in Chinese adult subjects with unresectable advanced carcinoma.

Conditions

  • Solid Tumors

Interventions

  • KN035Drug

    KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicities (DLTs) in dose escalation studyTime frame: From screening to up to cycle 1 (28 days)
  2. Percentage of participants with adverse events (AEs), serious adverse events and AEs of special interestTime frame: From screening to up to 1 months after the last dose of study drug (up to approximately 2 years)
  3. ORR of HCC patients in dose expansion studyTime frame: Up to 2 approximately years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hospital of Military academy of medical sciences

    Beijing, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Zhongshan Hospital affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.